Literature DB >> 29795134

Pharmacological actions of miltirone in the modulation of platelet function.

Wei Song1,2, Yuan-Yuan Ma1,2, Shuo Miao1,2, Ru-Ping Yang1,2, Ying Zhu1,2, Dan Shu1,2, Meng Lu1,2, Rong Ma1,2, Zhang-Yin Ming3,4,5.   

Abstract

Salvia miltiorrhiza Bunge contains various active constituents, some of which have been developed as commercially available medicine. Moreover, some other ingredients in Salvia miltiorrhiza play roles in anti-platelet activity. The aim of the present study was to investigate the effects and the underlying mechanism of miltirone, a lipophilic compound of Salvia miltiorrhiza Bunge. The ability of miltirone to modulate platelet function was investigated by a variety of in vitro and in vivo experiments. Platelet aggregation and dense granule secretion induced by various agonists were measured with platelet aggregometer. Clot retraction and spreading were imaged by digital camera and fluorescence microscope. Ferric chloride-induced carotid injury model and pulmonary thromboembolism model were used to check miltirone antithrombotic effect in vivo. To elucidate the mechanisms of anti-platelet activity of miltirone, flow cytometry and western blotting were performed. Miltirone (2, 4, 8 µM) was shown to suppress platelet aggregation, dense granule, and α granule secretion in a dose-dependent manner. Meanwhile, miltirone inhibited the clot retraction and spreading of washed platelets. It reduced the phosphorylation of PLCγ2, PKC, Akt, GSK3β and ERK1/2 in the downstream signal pathway of collagen receptor. It also reduced the phosphorylation of Src and FAK in the integrin αIIbβ3-mediated "outside-in" signaling, while it did not suppress the phosphorylation of β3. In addition, miltirone prolonged the occlusion time and reduced collagen/epinephrine-induced pulmonary thrombi. Miltirone suppresses platelet "inside-out" and "outside-in" signaling by affecting PLCγ2/PKC/ERK1/2, PI3K/Akt, and Src/FAK signaling. Therefore, miltirone might represent a potential anti-platelet candidate for the prevention of thrombotic disorders.

Entities:  

Keywords:  anti-platelet; glycoprotein VI pathway; integrin αIIbβ3; miltirone

Mesh:

Substances:

Year:  2018        PMID: 29795134      PMCID: PMC6329759          DOI: 10.1038/s41401-018-0010-1

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  6 in total

Review 1.  Pyroptosis and pyroptosis-inducing cancer drugs.

Authors:  Fan Yang; Sahana N Bettadapura; Mark S Smeltzer; Hua Zhu; Shanzhi Wang
Journal:  Acta Pharmacol Sin       Date:  2022-03-14       Impact factor: 7.169

2.  Hsp47 Inhibitor Col003 Attenuates Collagen-Induced Platelet Activation and Cerebral Ischemic-Reperfusion Injury in Rats.

Authors:  Shuang Wu; Chengwei Liang; Xiaoyun Xie; Haiping Huang; Jinfeng Fu; Cilan Wang; Zhiheng Su; Youqiong Wang; Xiang Qu; Jinpin Li; Jingli Liu
Journal:  Front Pharmacol       Date:  2022-01-10       Impact factor: 5.810

3.  Fruitflow inhibits platelet function by suppressing Akt/GSK3β, Syk/PLCγ2 and p38 MAPK phosphorylation in collagen-stimulated platelets.

Authors:  Huilian Chen; Shenghao Zhang; Hui Wang; Li Bao; Wei Wu; Ruomei Qi
Journal:  BMC Complement Med Ther       Date:  2022-03-17

4.  Molecular Mechanism of Salvia miltiorrhiza Bunge in Treating Cerebral Infarction.

Authors:  Xietao Ye; Jiali Liu; Xinyao Yuan; Songhong Yang; Yi Huang; Yan Chen
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-29       Impact factor: 2.629

5.  Tentative exploration of pharmacodynamic substances: Pharmacological effects, chemical compositions, and multi-components pharmacokinetic characteristics of ESZWD in CHF-HKYd rats.

Authors:  Li-Li Hong; Yan Zhao; Wei-Dong Chen; Chen-Yu Yang; Guo-Zhuan Li; Hong-Song Wang; Xiao-Yu Cheng
Journal:  Front Cardiovasc Med       Date:  2022-09-14

Review 6.  Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment.

Authors:  Sheng-Kai Hsu; Chia-Yang Li; I-Ling Lin; Wun-Jyun Syue; Yih-Fung Chen; Kai-Chun Cheng; Yen-Ni Teng; Yi-Hsiung Lin; Chia-Hung Yen; Chien-Chih Chiu
Journal:  Theranostics       Date:  2021-08-12       Impact factor: 11.556

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.